Genmab — Februar 2024

[JKY_VH]

haha Klarussen, ikke helt skævt

[Bulder]

Rally i US. NASDAQ +1,3%. Gode teknikregnskaber. NASDAQ future +2,2%. VIX -3%

[Riis7]

Meta oppe med 14 %

[Sukkeralf]

A Phase 1/2, Open-label, Dose-finding Trial With Expansion Cohorts to Evaluate the Safety and Antitumor Activity of GEN1056 (IgG1-PD1) as Monotherapy or Combination Therapy With GEN1042 in Subjects With Advanced Solid Tumors.

[Sukkeralf]

Mon target for GEN1056 afsløres lidt her?

[Helge_LarsenPI-redaktør]

Godmorgen. Ny rekord i januar og ATH med 103.000 unikke besøgende på Proinvestor.com

[Helge_LarsenPI-redaktør]

Tak for indsatsen til alle jer skrivende brugere og til jer som læser med.

[LP90]

Godmorgen

[bibob]

God morgen.

[E_L]

Nivolumab is IgG4 PD-1 , isnt't it? and Pembrolizumab

[E_L]

not sure where you found that Sukkeralf, but would be another confirmation of GEN1042 also then if that is a new trial?

[E_L]

annual US price change for Darzalex 6.3%, Tecvayli 5.0%, Rybrevant 4.0% (Sarclisa was +2.5%, like last year when Sanofi also did another hike in the summer)

[E_L]

talking about sarclisa; they sold €103mn in Q4 for a total of €381mn full year '23

[Sukkeralf]

https://www.fundacionhm.com/lineas-de-investigación/unidades/ensayos-clinicos-activos/fases-i-start-madrid

[Sukkeralf]

Scroll down to the right study

[Sukkeralf]

But maybe its the title thats wrong

[E_L]

well, it would fit Jan's comment:

af Jan Van de Winkel
GEN1056 is going to be positioned very broadly as a potential combination therapy for multiple other Genmab next generation antibody therapeutics.

[E_L]

Major bank sees positive signals in Lundbeck's MSA study despite missed endpoint https://medwatch.com/News/Pharma___Biotech/article16812127.ece

[Sukkeralf]

But why keep it a secret - others are pursuing the same…….
unless Genmab has another nice new feature.

[E_L]

don't know...